Osiris Therapeutics (OSIR) surges another 12.9% following the approval in New Zealand last week...

|About: Osiris Therapeutics, Inc. (OSIR)|By:, SA News Editor

Osiris Therapeutics (OSIR) surges another 12.9% following the approval in New Zealand last week of Prochymal, the company's stem-cell therapy for acute graft-vs-host disease in children who have undergone bone marrow transplants. (previous)